On 26 October 2026, Celltrion announced that its US subsidiary has signed an exclusive supply agreement with a major US healthcare company for its pre-filled syringe (PFS) formulation of Omlyclo®, biosimilar to Genentech/Novartis’ Xolair® (omalizumab), and its intravenous and subcutaneous formulations of Avtozma® (CT-P47), biosimilar to Roche’s RoActemra® (tocilizumab). The unidentified US healthcare company owns various large hospitals, insurance companies and pharmacy benefit managers (PBMs) across the US. Under the agreement, Omlyclo® and Avtozma® will be listed as the sole preferred products on the insurers’ formularies and supplied to affiliated medical institutions. Insured patients who receive a prescription of either product will be able to receive treatment under their insurance coverage. Product supply and insurance coverage began in October 2026. Celltrion’s Omlyclo® was launched in the US in October 2026, following approval in March 2025 (75 mg/0.5ml and 150 mg/ml PFS forms) and December 2025 (300mg formulation). Leveraging its first-mover advantage as the first omalizumab biosimilar launched in the US, Celltrion is expanding its supply channels for Omlyclo®. In October 2026, Celltrion signed a separate supply contract for Omlyclo® with a major global US distributor. Additionally, Celltrion is conducting formulary listing negotiations with multiple PBMs, with the contracts expected to finalise within Q4 of 2026. Both intravenous and subcutaneous formulations of Avtozma® were first approved in the US in January 2025, with the IV formulation launched in October 2025. In December 2025, Celltrion secured reimbursement coverage for Avtozma® IV in the US, with patient reimbursement available from January 2026. On 16 October 2026, Genentech and Novartis commenced BPCIA proceedings in the US District Court for the District of Delaware against Amneal Pharmaceuticals and its subsidiary, Kashiv BioSciences, relating to Kashiv’s efforts to bring an omalizumab biosimilar to the US market. Genentech and Novartis are alleging infringement of 9 US patents relating to antibody manufacturing processes, cell culture media, protein production methods, and the use of anti-IgE antibodies for the treatment of food allergies (12,371,728, 12,371,510, 8,574,869, 11,078,294, 11,987,637, 8,986,957, 9,243,224, 12,030,959 and 12,492,265). The dispute centres on ADL-018, biosimilar to Genentech/Novartis’ Xolair® (omalizumab), which was developed by Kashiv and licensed to Amneal for exclusive commercialisation in the US. Amneal announced the submission of its Biologics License Application (BLA) for ADL-018 to the FDA on 26 September 2025, paving the way for regulatory review of the product. In May 2026, Amneal and Kashiv filed an inter partes review (IPR) petition challenging the validity of US Patent No. 12,030,959, one of the patents in suit in the BPCIA proceedings, which relates to methods of treating food allergies in paediatric patients using omalizumab. The petition argues that the claimed methods lack novelty and/or are obvious in light of prior clinical trial publications. Kashiv has entered into agreements for the commercialisation of ADL-018 in other regions, including with CRISTÁLIA for LATAM markets (August 2025), MS Pharma for MENA markets (August 2025) and Alvotech for the EU, UK, Australia, Canada and New Zealand (AVT23, October 2023). An application for ADL-018 was accepted for review by Health Canada in June 2026 and marketing applications for AVT23 were accepted by the UK’s MHRA in March 2025 and the European Medicines Agency in October 2025. In September 2026, Alvotech/Advanz Pharma’s Adcomfo® (AVT23/ADL-018) was recommended by the CHMP for approval in 75 mg, 150 mg and 300 mg solution for injection in a pre-filled syringe (PFS) or pre-filled pen (PFP). Celltrion’s Omlyclo® is currently the only omalizumab biosimilar on the market anywhere in the world. Omlyclo® was launched in the US in October 2026 (approved March 2025 (75 mg/0.5ml and 150 mg/ml PFS forms) and December 2025 (300mg formulation)). Celltrion completed its launch of Omlyclo® (75mg and 150mg) in major European countries, including Germany, Spain, the UK and France, in November 2025 and launched the high dose formulation in Europe in August 2026. In late November 2025, Celltrion announced that it launched Omlyclo® in Brazil. Teva’s biosimilar omalizumab applications have been accepted for review in the US and EU (March 2026) and CuraTeQ announced Phase 3 study results for its biosimilar omalizumab, BP11, in April 2026. Mabpharm claims to have had an omalizumab biosimilar (Aomaishu®) approved for marketing in China in May 2023. On 6 October 2026, Celltrion announced the US launch of Omlyclo®, biosimilar to Genentech/Novartis’ Xolair® (omalizumab). Omlyclo® is the first omalizumab biosimilar on the US market and is available in three dosage forms: 75 mg, 150 mg and 300 mg. Omlyclo® was first approved in the US in March 2025, in 75 mg/0.5ml and 150mg/ml PFS forms, with full interchangeable status. The 300 mg formulation was FDA approved in December 2025. The European launch of Omlyclo® in 75 mg and 150 mg dosage forms commenced in September 2025 and was completed in November 2025. The high dose (300 mg) dosage form was launched in Europe in August 2026. Omlyclo® to date remains the only omalizumab biosimilar approved in the EU, with Celltrion receiving EU market authorisation for its 75 mg/0.5 mL and 150 mg/1 mL PFS formulations in May 2024, and approval for the 300 mg formulation in November 2025 Omalizumab biosimilars in development include Kashiv BioSciences/Alvotech’s ADL-018/AVT23, with an application for ADL-018 accepted for review by Health Canada in June 2026 and marketing applications for AVT23 accepted by the UK’s MHRA in March 2025 and the European Medicines Agency in October 2025. Under an exclusive licensing agreement with Kashiv entered in October 2023, Alvotech holds the commercialisation rights to ADL-018/AVT23 in Canada, together with the European Economic Area, UK, Switzerland, Australia and New Zealand. Kashiv has entered into agreements for commercialisation of ADL-018 with Cristália for LATAM (August 2025) and MS Pharma for MENA markets (August 2025). Teva’s biosimilar omalizumab applications have been accepted for review in the US and EU (March 2026) and CuraTeQ announced Phase 3 study results for its biosimilar omalizumab, BP11, in April 2026. Mabpharm claims to have had an omalizumab biosimilar (Aomaishu®) approved for marketing in China in May 2023. On 1 October 2026, Celltrion’s Avtozma® (tocilizumab), biosimilar to Genentech’s Actemra®, became the first tocilizumab biosimilar to be listed on Australia’s Schedule of Pharmaceutical Benefits (PBS). The PBS listing of Avtozma® will result in a mandatory 25% statutory price reduction for Actemra®. Avtozma® was the first, and remains the only, tocilizumab biosimilar to be approved in Australia (May 2025). It was launched in Korea in June 2025. in the US (IV formulation) in October 2025, and in Europe in January 2026. The biosimilar has also been granted marketing authorisation in a number of other regions, including Japan (September 2022) and New Zealand (December 2025). Celltrion additionally had the following products listed on the PBS on 1 October 2026: On 18 September 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) announced the outcomes of its September 2026 meeting, including positive opinions for the following two biosimilars. Alvotech/Advanz Pharma’s Adcomfo® (AVT23/ADL-018), biosimilar to Genentech/Novartis’ Xolair® (omalizumab), is recommended for approval in 75 mg, 150 mg and 300 mg solution for injection in a pre-filled syringe (PFS) or pre-filled pen (PFP). The CHMP opinion follows EMA acceptance of the marketing authorisation application for AVT23 in October 2025. Adcomfo® was developed by Alvotech in collaboration with Kashiv Biosciences and is the subject of an October 2023 licensing agreement under which Advanz Pharma has exclusive commercialisation rights for the European Economic Area (European Union, Norway, Iceland and Lichtenstein), the UK, Switzerland, Canada, Australia and New Zealand. A marketing application for AVT23 was accepted by the UK’s MHRA in March 2025. Celltrion’s Omlyclo® was the first (and to date remains the only) omalizumab biosimilar to be approved in the EU, with Celltrion receiving EU market authorisation for its 75 mg/0.5 mL and 150 mg/1 mL PFS formulations in May 2024, and approval for the 300 mg formulation in November 2025. Celltrion commenced its European rollout of Omlyclo® (75 mg/0.5 mL and 150 mg/1 mL) in Norway in September 2025, and completed the launch of those formulations in major European countries including Germany, Spain, the UK and France in November 2025. Teva’s biosimilar omalizumab applications have been accepted for review in the US and EU (March 2026) and CuraTeQ announced Phase 3 study results for its biosimilar omalizumab, BP11, in April 2026. Mabpharm claims to have had an omalizumab biosimilar (Aomaishu®) approved for marketing in China in May 2023. The CHMP has also recommended Biocon’s Pebrilzo® (Bmab 1500), biosimilar to Roche/Genentech’s Perjeta® (pertuzumab), for the treatment of HER-2 positive breast cancer (420 mg concentrate for solution for infusion). Pebrilzo® follows Shanghai Henlius/Organon’s pertuzumab biosimilar, Poherdy®, which was approved in Europe in April 2026 (and in the US (November 2025) and China (as Hanbeiyou®, May 2026)). Biocon is currently being sued by Roche/Genentech in the US in relation to Bmab 1500, with BPCIA proceedings commenced in July 2026. Roche/Genentech allege Biocon infringes 28 US patents for inventions related to Perjeta® and various manufacturing methods for antibody production, covering pertuzumab as well as its use and manufacture. Genentech also filed an ITC complaint in February 2026 against Biocon’s importation of Bmab 1500 into the US. Approvals for pertuzumab biosimilars have been granted in India for Intas’ product (December 2024), Zydus’ Sigrima™ (June 2024) and Enzene’s Pertuza®/Perzea® (launched September 2025). In Russia, Biocad’s Pertuvia™ (May 2025) and R-Pharm’s Persinthia™ (February 2026) are approved. Litigation has been brought by Roche/Genentech against Biocad in Russia and Zydus in India. In June 2026, EirGenix announced that it signed an agreement with an undisclosed company for the licensing and commercialisation of its pertuzumab biosimilar, EG1206A, in Japan. This followed a 2025 global commercialisation deal with Sandoz for EG1206A, excluding Japan and a number of other countries in Asia. On 11 September 2026, Celltrion’s Omlyclo®, biosimilar to Genentech/Novartis’ Xolair® (omalizumab), was approved in Australia in a 300 mg/2 mL solution for injection in pre-filled pen (PFP) and pre-filled syringe (PFS) forms. The Australian approval follows launch of the 300 mg formulation of Omlyclo® in Europe (August 2026) and Korea (March 2026) and its approval in a number of other countries including the US (December 2025) and Canada (January 2026). Omlyclo® is the only biosimilar omalizumab to have been approved in Australia, with the 75 mg/ 0.5 mL and 150 mg/1 mL PFS PBS-listed on 1 August 2025 and launched in Australia in September 2025, and the 75 mg/ 0.5 mL and 150 mg/1 mL PFP TGA-approved in August 2025 and recommended for PBS listing in April 2026. Omalizumab biosimilars in development include Kashiv BioSciences/Alvotech’s ADL-018/AVT23, with an application for ADL-018 accepted for review by Health Canada in June 2026 and marketing applications for AVT23 accepted by the UK’s MHRA in March 2025 and the European Medicines Agency in October 2025. Under an exclusive licensing agreement with Kashiv entered in October 2023, Alvotech holds the commercialisation rights to ADL-018/AVT23 in Canada, together with the European Economic Area, UK, Switzerland, Australia and New Zealand. Kashiv has entered into agreements for commercialisation of ADL-018 with Cristália for LATAM (August 2025) and MS Pharma for MENA markets (August 2025). Teva’s biosimilar omalizumab applications have been accepted for review in the US and EU (March 2026) and CuraTeQ announced Phase 3 study results for its biosimilar omalizumab, BP11, in April 2026. Mabpharm claims to have had an omalizumab biosimilar (Aomaishu®) approved for marketing in China in May 2023. On 25 August 2026, Celltrion announced that it has launched Omlyclo® 300 mg, biosimilar to Genentech/Novartis’ Xolair® (omalizumab), in Europe, commencing in Germany, the UK and France. Omlyclo® was the first (and remains the only) omalizumab biosimilar to be approved in the EU, with Celltrion receiving EU market authorisation for its 75 mg/0.5 mL and 150 mg/1 mL PFS formulations in May 2024, and approval for the 300 mg formulation following in November 2025. Celltrion commenced its European rollout of Omlyclo® (75 mg/0.5 mL and 150 mg/1 mL) in Norway in September 2025, and completed the launch of those formulations in major European countries including Germany, Spain, the UK and France in November 2025. The 300 mg formulation of Omlyclo® has also been launched in Korea (30 March 2026) and approved in a number of countries including the US (December 2025) and Canada (January 2026). Omalizumab biosimilars in development include Kashiv BioSciences/Alvotech’s ADL-018/AVT23, with an application for ADL-018 accepted for review by Health Canada in June 2026 and marketing applications for AVT23 accepted by the UK’s MHRA in March 2025 and the European Medicines Agency in October 2025. Under an exclusive licensing agreement with Kashiv entered in October 2023, Alvotech holds the commercialisation rights to ADL-018/AVT23 in Canada, together with the European Economic Area, UK, Switzerland, Australia and New Zealand. Kashiv has entered into agreements for commercialisation of ADL-018 with Cristália for LATAM (August 2025) and MS Pharma for MENA markets (August 2025). Teva’s biosimilar omalizumab applications have been accepted for review in the US and EU (March 2026) and CuraTeQ announced Phase 3 study results for its biosimilar omalizumab, BP11, in April 2026. Mabpharm claims to have had an omalizumab biosimilar (Aomaishu®) approved for marketing in China in May 2023. On 1 July 2026, Seoul Economic Daily reported that Celltrion has launched its new Omlyclo® (omalizumab) Pen Injection 150mg, an autoinjector formulation designed for the treatment of allergic asthma and chronic idiopathic urticaria. Celltrion announced the Korean approval of the autoinjector presentation of Omlyclo®, biosimilar to Novartis’ Xolair®, in December 2025. The launch comes three months after Celltrion’s Korean launch of its high dose (300 mg) Omlyclo® formulation. Celltrion’s Omlyclo® (CT-P39) is currently the only omalizumab biosimilar on the market anywhere in the world. Omlyclo® was approved in the US in March 2025 (75 mg/0.5ml and 150 mg/ml PFS forms) and in December 2025 (300mg formulation). Celltrion commenced its European rollout of Omlyclo® with the launch of the product in Norway in September 2025, and completed its launch in major European countries including Germany, Spain, the UK and France in November 2025. In late November 2025, Celltrion announced that it launched Omlyclo® in Brazil, while in January 2026, high dose Omlyclo® (PFS and autoinjector) was approved in Canada. Kashiv BioSciences/Alvotech are likely to be the next companies with an approved omalizumab biosimilar on the market. Under an exclusive licensing agreement with Kashiv entered in October 2023, Alvotech holds the commercialisation rights to ADL-018 (also referred to as AVT23) in Canada, together with the European Economic Area, UK, Switzerland, Australia and New Zealand. An application for ADL-018 was accepted for review by Health Canada in June 2026 and marketing applications for AVT23 were accepted by the UK’s MHRA in March 2025 and by the European Medicines Agency in October 2025. Kashiv has entered into agreements for commercialisation of ADL-018 with Cristália for LATAM (August 2025) and MS Pharma for MENA markets (August 2025). Omalizumab biosimilars are also in development by at least CuraTeQ (Ph 3 study results announced April 2026) and Teva (acceptance for review of biosimilar omalizumab applications in US and EU announced March 2026). On 4 June 2026, Kashiv BioSciences announced that Health Canada has accepted for review the market authorisation application (MAA) for ADL-018, biosimilar to Genentech/Novartis’ Xolair® (omalizumab). Under an exclusive licensing agreement with Kashiv entered in October 2023, Alvotech holds the commercialisation rights to ADL-018 (also referred to as AVT23) in Canada, together with the European Economic Area, UK, Switzerland, Australia and New Zealand. The Canadian filing follows a series of regulatory advances for ADL-018. Marketing applications for ADL-018 were accepted by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in March 2025 and by the European Medicines Agency (EMA) in October 2025. Beyond Canada, Kashiv has agreements for the commercialisation of ADL-018 with Brazilian pharmaceutical company, CRISTÁLIA, for the Latin American market (11 August 2025) and MS Pharma for MENA markets (August 2025). The only omalizumab biosimilar currently approved in Canada, and anywhere else in the world, is Celltrion’s Omlyclo®. Omlyclo® was approved in Canada in 75mg and 150mg formulations in December 2024 and in 300mg PFS and autoinjector presentations in January 2026. Omlyclo® has also been approved in: the EU (May 2024 and November 2025 (300mg)); Korea (June 2024 (PFS), December 2025 (autoinjector), 300mg formulation launched 30 March 2026)); Australia (November 2024); the US (March 2025 (75 mg/0.5ml and 150 mg/ml PFS) and December 2025 (300mg)); New Zealand (April 2025); and Japan (March 2026). Celltrion commenced its European rollout of Omlyclo® in Norway in September 2025, and completed its launch in major European countries including Germany, Spain, the UK and France in November 2025. In late November 2025, Celltrion announced that it launched Omlyclo® in Brazil. Omalizumab biosimilars are also in development by at least CuraTeQ (Ph 3 study results announced April 2026) and Teva (acceptance for review of biosimilar omalizumab applications in US and EU announced March 2026). On 26 May 2026, Amneal Pharmaceuticals and Kashiv Biosciences filed a petition with the Patent Trial and Appeal Board for inter partes review of Genentech/Novartis’ US Patent No. 12,030,959. The patent relates to methods for treating food allergies in paediatric patients by administering omalizumab. Amneal and Kashiv argue that the claims of the US959 patent are invalid because they lack novelty and/or are obvious, including in light of articles disclosing the results of phase 1 or 2 clinical trials of omalizumab in patients with food allergies. Amneal submitted a Biologics Licence Application (BLA) to the FDA for its omalizumab (ADL-018), biosimilar to Genentech/Novartis’ Xolair®, in September 2025. ADL-018 was developed by Kashiv, with Amneal holding exclusive US commercialisation rights for the product, under a July 2024 licensing agreement. Kashiv has also entered into agreements for the commercialisation of ADL-018 in other regions, including with CRISTÁLIA for LATAM markets (August 2025), MS Pharma for MENA markets (August 2025) and Alvotech for the EU, UK, Australia, Canada and New Zealand (AVT23, October 2023). A marketing application for AVT23 was accepted by the UK’s MHRA in March 2025. Celltrion’s Omlyclo® is currently the only omalizumab biosimilar on the market anywhere in the world. Omlyclo® was approved in the US in March 2025 (75 mg/0.5ml and 150 mg/ml PFS forms) and in December 2025 (300mg formulation). Celltrion commenced its European rollout of Omlyclo® with the launch of the product in Norway in September 2025, and completed its launch in major European countries including Germany, Spain, the UK and France in November 2025. In late November 2025, Celltrion announced that it launched Omlyclo® in Brazil. Omalizumab biosimilars are in development, including by Teva (acceptance of regulatory applications for review by the FDA and EMA announced March 2026) and CuraTeQ (phase 3 biosimilar omalizumab trial completed April 2026).2026
Product specific reports based on extracts from our BioBlast® database
aflibercept | Eylea® | Regeneron
bevacizumab | Avastin® | Roche/Genentech
cetuximab | Erbitux® | Eli Lilly/Merck KGaA
darbepoetin | Aranesp® | Amgen
denosumab | Prolia®/Xgeva® | Amgen
dupilumab | Dupixent® | Sanofi-Aventis
eculizumab | Soliris® | Alexion
filgrastim (GCSF) | Neupogen® | Amgen
golimumab | Simponi® | Janssen
guselkumab | Tremfya® | Janssen
infliximab | Remicade® | Johnson & Johnson
ixekizumab | Taltz® | Eli Lilly
lecanemab | Leqembi® | Eisai/Biogen
liraglutide | Victoza® /Saxenda® | Novo Nordisk
natalizumab | Tysabri® | Biogen/Elan
olaparib | Lynparza® | AstraZeneca/Merck
omalizumab | Xolair® | Genentech / Novartis
pegfilgrastim | Neulasta® | Amgen
pembrolizumab | Keytruda® | MSD
ranibizumab | Lucentis® | Genentech
regdanvimab | Regkirona® | Celltrion
risankizumab | Skyrizi® | AbbVie
rituximab | Rituxan®/MabThera® | Genentech/Biogen
secukinumab | Cosentyx® | Novartis
semaglutide | Wegovy®/Ozempic® | Novo Nordisk
tocilizumab | Actemra® | Roche
trastuzumab | Herceptin® | Roche/Genentech
ustekinumab | Stelara® | Johnson & Johnson/Janssen
Biosimilars Deals
BioBlast® Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

